Trial Profile
A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients With Metastatic High Grade Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Therapeutic Use
- 01 Jul 2021 Results assessing Impacts of pembrolizumab therapy on immune phenotype in high grade neuroendocrine neoplasms published in the Cancer Immunology Immunotherapy
- 16 Feb 2021 Status changed from active, no longer recruiting to completed.
- 03 Jun 2020 Planned End Date changed from 1 Mar 2020 to 1 Sep 2020.